Comprehensive genetic analysis in patients with clinically well characterized ALPID could potentially help select targeted therapies.
Inborn errors of immunodeficiency (IEI) that present with benign lymphoproliferation and immune cytopenia vary in severity and can be difficult to diagnose and treat. IEIs that present with mutations in the Fas signaling pathway are known as autoimmune lymphoproliferative syndrome (ALPS), which has a benign clinical course, and those without such mutations are known as ALPS-like diseases, which can be fatal and require curative therapy with hematopoietic stem cell transplant. These researchers suggested a new umbrella term — autoimmune lymphoproliferative immunodeficiency (ALPID) phenotype — for the spectrum of these conditions.
In a prospective, observational study, the researchers evaluated clinical, immunological, and genetic features for…
Reviewing Author
DisclosuresConsultant/Advisory BoardGenentech
Grant/Research SupportX4 Pharma; Pfizer; Health Resources and Services Administration; American Thrombosis and Hemostasis Network/CDC; Carver College of Medicine
Leadership Positions in Professional SocietiesInternational Society on Thrombosis and Haemostasis (Finance Committee Member); American Society of Hematology Clinical Research Translational Institute
DisclosuresConsultant/Advisory BoardGenentech
Grant/Research SupportX4 Pharma; Pfizer; Health Resources and Services Administration; American Thrombosis and Hemostasis Network/CDC; Carver College of Medicine
Leadership Positions in Professional SocietiesInternational Society on Thrombosis and Haemostasis (Finance Committee Member); American Society of Hematology Clinical Research Translational Institute